Arkolith/Insider Trading/CRNX/Form 4

Kalofonos Isabel

Chief Commercial OfficerCrinetics Pharmaceuticals, Inc. (CRNX) · full profile →Form 4 · filed Jan 7, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$138K
Net Open-Market Flow
-$138K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 5, 2026Option exercise(M)3K$40.59$101K3K
Jan 5, 2026Sell(S)3K$55.00$138K834

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 5, 2026Option exercise(M)3K—$098K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-001230) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML